Mihaela Popa

Mihaela Popa

Auto-generated profile, based on publicly available information

Mihaela Popa

Precision Oncology Research Group, University of Bergen, Bergen, Norway

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2025 in Cancer Research
Verified
Journal Article
Open access
JEJohanna Eriksson
Johanna Eriksson
SZShuyu Zheng
Shuyu Zheng
MPMihaela Popa
Mihaela Popa
JBJie Bao
Jie Bao
JDJun Dai
Jun Dai
Jing TangJing Tang
Jing Tang
Whereas FMS-like tyrosine kinase-3 (FLT3) inhibitors have significantly improved the treatment of aggressive FLT3-mutated acute myeloid leukemia (AML), the emergence of resistance remains as a major challenge. In this study, we applied our recently developed single-cell lineage-tracing method ReSisTrace to identify cells that are intrinsically resistant or sensitive to the FLT3 inhibitors midostaurin and quizartinib in AML with FLT3-ITD mutations. Comparison of the gene expression profiles of these cells revealed transcriptional resistance signatures, including upregulation of GSPT1. Depletion of GSPT1 with CRISPR-Cas9–mediated knockout resulted in increased sensitivity of AML cells to quizartinib treatment. Furthermore, targeting GSPT1 with the small molecule CC-90009 exhibited strong synergistic effects when combined with FLT3 inhibitors in the FLT3-ITD cell lines and primary AML patient samples. In addition, in an FLT3-ITD–positive AML patient-derived xenograft mouse model, the CC-90009 and quizartinib combination showed significantly higher antitumor efficacy and prolonged overall survival compared with either treatment alone. Furthermore, compounds that induced transcriptomic changes opposite to the resistance signatures prompted cells to acquire FLT3 inhibitor–sensitive states. Vistusertib (mTOR inhibitor), linsitinib (IGF1R and INSR inhibitor), and meisoindigo (IGF1R and SRC family kinase inhibitor), all inhibiting pathways parallel to or downstream of oncogenic FLT3 signaling, were predicted and validated to sensitize FLT3-mutated cell lines and primary cells to FLT3 inhibitors. Collectively, these findings demonstrate the ability of ReSisTrace to unveil preexisting transcriptional features of treatment vulnerability in hematologic cancers and elucidate strategies for enhancing FLT3 inhibitor treatment efficacy in FLT3-ITD–mutated AML. Significance: Single-cell lineage tracing with ReSisTrace reveals cellular states that prime treatment resistance and identifies approaches to sensitize FLT3-ITD–positive acute myeloid leukemia to FLT3 inhibitors.

2 April 2026
Verified
Other
Open access
JEJohanna Eriksson
Johanna Eriksson
SZShuyu Zheng
Shuyu Zheng
MPMihaela Popa
Mihaela Popa
JBJie Bao
Jie Bao
JDJun Dai
Jun Dai
Jing TangJing Tang
Jing Tang
Fig. S4 shows GSPT1 protein expression and cell growth analyses under normal culture conditions, as well as cell viability analyses following FLT3 inhibitor treatment of control and GSPT1-knockout MOLM-13 cells.

2 April 2026
Verified
Other
Open access
JEJohanna Eriksson
Johanna Eriksson
SZShuyu Zheng
Shuyu Zheng
MPMihaela Popa
Mihaela Popa
JBJie Bao
Jie Bao
JDJun Dai
Jun Dai
Jing TangJing Tang
Jing Tang
Whereas FMS-like tyrosine kinase-3 (FLT3) inhibitors have significantly improved the treatment of aggressive FLT3-mutated acute myeloid leukemia (AML), the emergence of resistance remains as a major challenge. In this study, we applied our recently developed single-cell lineage-tracing method ReSisTrace to identify cells that are intrinsically resistant or sensitive to the FLT3 inhibitors midostaurin and quizartinib in AML with FLT3-ITD mutations. Comparison of the gene expression profiles of these cells revealed transcriptional resistance signatures, including upregulation of GSPT1. Depletion of GSPT1 with CRISPR-Cas9–mediated knockout resulted in increased sensitivity of AML cells to quizartinib treatment. Furthermore, targeting GSPT1 with the small molecule CC-90009 exhibited strong synergistic effects when combined with FLT3 inhibitors in the FLT3-ITD cell lines and primary AML patient samples. In addition, in an FLT3-ITD–positive AML patient-derived xenograft mouse model, the CC-90009 and quizartinib combination showed significantly higher antitumor efficacy and prolonged overall survival compared with either treatment alone. Furthermore, compounds that induced transcriptomic changes opposite to the resistance signatures prompted cells to acquire FLT3 inhibitor–sensitive states. Vistusertib (mTOR inhibitor), linsitinib (IGF1R and INSR inhibitor), and meisoindigo (IGF1R and SRC family kinase inhibitor), all inhibiting pathways parallel to or downstream of oncogenic FLT3 signaling, were predicted and validated to sensitize FLT3-mutated cell lines and primary cells to FLT3 inhibitors. Collectively, these findings demonstrate the ability of ReSisTrace to unveil preexisting transcriptional features of treatment vulnerability in hematologic cancers and elucidate strategies for enhancing FLT3 inhibitor treatment efficacy in FLT3-ITD–mutated AML.Significance:Single-cell lineage tracing with ReSisTrace reveals cellular states that prime treatment resistance and identifies approaches to sensitize FLT3‐ITD–positive acute myeloid leukemia to FLT3 inhibitors.

2 April 2026
Verified
Other
Open access
JEJohanna Eriksson
Johanna Eriksson
SZShuyu Zheng
Shuyu Zheng
MPMihaela Popa
Mihaela Popa
JBJie Bao
Jie Bao
JDJun Dai
Jun Dai
Jing TangJing Tang
Jing Tang
Table S6 shows significant BioCarta pathways for the gene expression signatures.

2 April 2026
Verified
Other
Open access
JEJohanna Eriksson
Johanna Eriksson
SZShuyu Zheng
Shuyu Zheng
MPMihaela Popa
Mihaela Popa
JBJie Bao
Jie Bao
JDJun Dai
Jun Dai
Jing TangJing Tang
Jing Tang
Fig. S5 shows viability measurements and dose–response analyses of two FLT3-ITD-mutated primary AML samples cultured under different conditions and treated with various drugs in combination with FLT3 inhibitors.

2 April 2026
Verified
Other
Open access
JEJohanna Eriksson
Johanna Eriksson
SZShuyu Zheng
Shuyu Zheng
MPMihaela Popa
Mihaela Popa
JBJie Bao
Jie Bao
JDJun Dai
Jun Dai
Jing TangJing Tang
Jing Tang
Table S4 shows fitness-related control gene expression signatures.